XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.26.1

STOCK OPTIONS AND WARRANTS | 9 Months Ended
--- | ---
Jan. 31, 2026
Share-Based Payment Arrangement [Abstract] |
STOCK OPTIONS AND WARRANTS | NOTE 6 – STOCK OPTIONS AND WARRANTS 2021 Equity Incentive Plan Effective June 30, 2021, the Company implemented the 2021 Equity Incentive Plan (“2021 Equity Plan”) as approved by the Company’s stockholders. The 2021 Equity Plan is administered by the Compensation Committee of the Board and has 166,667 shares authorized under this plan. The 2021 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (“ISOs”) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder). As of January 31, 2026, there are 154,596 shares remaining available under the 2021 Equity Plan. 2022 Equity Incentive Plan Effective December 28, 2022, the Company implemented the 2022 Equity Incentive Plan (“2022 Equity Plan”) as approved by the Company’s stockholders. In October 2025, the Company held a special meeting of stockholders (the “2025 Special Meeting”). At the 2025 Special Meeting, the stockholders of the Company approved an amendment to the 2022 Equity Plan which, among other things, increased the number of shares of common stock available for grant under the 2022 Equity Plan by 2,250,000. The 2022 Equity Plan is administered by the Compensation Committee of the Board and has 5,000,000 shares available under this plan, as amended. The 2022 Equity Plan can issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2022 Equity Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive stock options (“ISOs”) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted to any 10% shareholder). As of January 31, 2026, there are 2,970,040 shares remaining available under the 2022 Equity Plan. Stock Options A summary of the Company’s stock option activity and related information for the nine months ended January 31, 2026, are shown below:
Schedule of stock option activity |  |  |  |  |  |
Options |  | Number of Options |  | Weighted Average Exercise Price per Share |  | Weighted Average Remaining Contractual Term in Years
Outstanding, April 30, 2025 |  |  | 1,169,961 |  |  | $ | 2.21 |  |  |  | 8.62 |
Issued |  |  | – |  |  |  | – |  |  |  | – |
Expired and forfeited |  |  | (9,334 | ) |  |  | 10.78 |  |  |  | – |
Outstanding, January 31, 2026 |  |  | 1,160,627 |  |  | $ | 2.14 |  |  |  | 7.92 |
Exercisable, January 31, 2026 |  |  | 907,695 |  |  | $ | 2.39 |  |  |  | 7.56 |
The Company recorded $60,492 and $181,476 of stock-based compensation expense related to the issuance of Employee Options to certain officers and directors in exchange for services during the three and nine months ended January 31, 2026, respectively, and $72,859 and $414,692 for the three and nine months ended January 31, 2025, respectively. As of January 31, 2026, there remained $54,579 of unrecognized compensation expense related to unvested Employee Options granted to officers and directors. The aggregate intrinsic value of vested outstanding options as of January 31, 2026 was $0. Warrants Series B Warrant On May 10, 2023, the Company entered into a Securities Purchase Agreement (the “Private Placement Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors warrants to acquire up to an aggregate of 8,750,000 shares of Common Stock, collectively, the (“Series B Warrants”), with an exercise price of $4.00 per share (subject to adjustment), for a period of five years from the date of issuance. In connection with the Series C Private Placement (as defined herein), in August 2025, the exercise price of the Series B Preferred Warrants was adjusted to $0.95 per share and the number of shares of Common Stock issuable upon exercise of the Series B Warrants was adjusted proportionally to 36,780,161 pursuant to the full ratchet anti-dilution provisions contained therein. The Series B Warrants were determined to be subject to liability classification as they are considered to be indexed to the Company’s own stock but fail to meet the requirements for equity classification in accordance with ASC 815. As such, the Company recorded the Series B Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of the Series B Warrants issued on May 10, 2023. During the three and nine months ended January 31, 2026, the Company received Series B exercise notices totaling 1,100,000 shares. The exercises resulted in the Company received cash in the amount of $1,046,740 and a reduction in the warrant liability of $599,135. Following the exercises the Company has 35,680,160 Series B warrant shares remaining. During the three and nine months ended January 31, 2026, the Company recorded a gain of approximately $874,000 and a loss of $9,182,000, respectively, related to the change in fair value of the warrant liability which is recorded in other income on the unaudited condensed consolidated statements of operations. The fair value of the Series B Warrants of $9,520,000 was estimated at January 31, 2026, utilizing the Black-Scholes-Merton Model using the fair value of the Company’s common stock of $0.82 and the following weighted average assumptions: dividend yield 0%; remaining term of 2.27 years; equity volatility of 60.0%; and a risk-free interest rate of 3.48%. During the three and nine months ended January 31, 2025, the Company recorded a gain of approximately $4,487,000 and $8,400,000, respectively, related to the change in fair value of the warrant liability which is recorded in other income (expense) on the Condensed Consolidated Statements of Operations. The fair value of the Series B Warrants of $2,384,000 was estimated at January 31, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company’s common stock of $1.60 and the following weighted average assumptions: dividend yield 0%; remaining term of 3.27 years; equity volatility of 55.0%; and a risk-free interest rate of 4.19%. Settlement Warrants In connection with the Settlement Agreement, as defined on Note 8 – Commitments and Contingencies, on May 16, 2025, the Company issued warrants (“First Warrant Issuance”) to purchase 343,183 shares of Common Stock with an exercise price of $4.00 per share and a term of five years from the issuance date. On October 29, 2025, the Company issued additional warrants (“Additional Warrants”, and collectively with the First Warrant Issuance, the “Settlement Warrants”) to purchase 313,067 shares of the Company’s common stock with an exercise price of $4.00 per share and a term of five years from the issuance date. In connection with the Series C Private Placement (as defined herein), in August 2025, the exercise price of the Settlement Warrants was adjusted to $0.95 per share and the number of shares of Common Stock issuable upon exercise Settlement Warrants was adjusted proportionally to 2,758,511 pursuant to the full ratchet anti-dilution provisions contained in their respective agreements. The Settlement Warrants were determined to be subject to liability classification. As such, the Company recorded the Settlement Warrants as a liability upon issuance at their fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of the Settlement Warrants issued during the three and nine months ended January 31, 2026. The fair value of the First Warrant Issuance of approximately $199,000 was estimated at May 16, 2025 (the date of issuance) using the fair value of the Company’s common stock of $1.06 on the issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity volatility of 97.0%; and a risk-free interest rate of 4.1%. The fair value of the Additional Warrants of approximately $164,000 was estimated at July 29, 2025 (the date of issuance) using the fair value of the Company’s common stock of $1.02 on the issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity volatility of 94.0%; and a risk-free interest rate of 3.9%. During the three and nine months ended January 31, 2026, the Company recorded a gain on legal settlement of $0 and $106,000, respectively, which represents the difference between the estimated fair value of the Settlement Warrants recognized during the year ended April 30, 2025 totaling $469,000 and their issuance date fair values totaling $363,000. See Note 8 – Commitment and Contingencies – Legal Proceedings. During the three and nine months ended January 31, 2026, the Company recorded a gain of $545,000 and a loss of $694,000, respectively, related to the change in fair value of the warrant liability associated with the Settlement Warrants which is recorded in other income (expense) on the unaudited condensed consolidated statements of operations. The fair value of the Settlement Warrants of $1,057,000 was estimated at January 31, 2026 utilizing the Black-Scholes-Merton Model using the fair value of the Company’s common stock of $0.82 and was based on the following weighted average assumptions: expected dividend yield of 0%; expected term of 4.39 years; equity volatility of 60.0%; and a risk-free interest rate of 3.7%. Series C Warrant On August 17, 2025, the Company entered into a Securities Purchase Agreement (the “Series C Private Placement Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell in a private placement to the Investors warrants to acquire up to an aggregate of 7,000,000 shares of Common Stock, collectively, the (“Series C Preferred Warrant”), with an exercise price of $1.00 per share (subject to adjustment), for a period of five years from the date of issuance. The Series C Private Placement Agreement closed on August 19, 2025. The Series C Warrants were determined to be subject to liability classification as they are considered to be indexed to the Company’s own stock but fail to meet the requirements for equity classification in accordance with ASC 815. As such, the Company recorded the Series C Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. The fair value of the Series C Warrants of $5,220,000 was estimated at August 19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company’s common stock of $1.01 and the following weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility of 95.0%; and a risk-free interest rate of 3.75%. During the three and nine months ended January 31, 2026, the Company recorded a gain of approximately $1,076,000 and $2,140,000, respectively, related to the change in fair value of the warrant liability associated with the Series C Warrants which is recorded in other income on the unaudited condensed consolidated statements of operations. The fair value of the Series C Warrants of $3,080,000 was estimated at January 31, 2026, utilizing the Black-Scholes-Merton Model using the fair value of the Company’s common stock of $0.82 and the following weighted average assumptions: dividend yield 0%; remaining term of 4.55 years; equity volatility of 70.0%; and a risk-free interest rate of 3.68%. Placement Agent Warrants In connection with the Series C Private Placement Agreement, the Company also issued warrants to purchase up to an aggregate of 560,000 shares of the Common Stock as compensation to placement agents for services rendered (the “Series C Placement Agent Warrants”). The Series C Placement Agent Warrants are classified as a contingently redeemable warrant in accordance with ASC 718, as it was determined that the warrants were not precluded from equity classification under that guidance, but could be settled in cash or other assets in the event that another person or entity becomes the beneficial owner of 50% of the outstanding shares of the Common Stock. The Series C Placement Agent Warrants were thus classified in temporary equity on the Company’s condensed consolidated balance sheets as of January 31, 2026 pursuant to ASC 480-10-S99-3A. The fair value of the Series C Placement Agent Warrants of $417,000 was estimated at August 19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company’s common stock of $1.01 and the following weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility of 95.0%; and a risk-free interest rate of 3.75%. The fair value of the Series C Placement Agent Warrants was expensed as incurred and was recorded in Series C convertible preferred stock and warrants issuance costs on the condensed consolidated statement of operations for the nine months ended January 31, 2026. A summary of the Company’s warrant activity and related information for the nine months ended January 31, 2026, are shown below:
Schedule of warrant activity |  |  |  |  |  |
|  | Warrants |  | Weighted Average Exercise Price Per Share |  | Weighted Average Remaining Contractual Term In Years
Outstanding, April 30, 2025 |  |  | 18,570,847 |  |  | $ | 4.54 |  |  |  | 2.12 |
Issued |  |  | 8,216,250 |  |  |  | 1.00 |  |  |  | – |
Issued - Series B Warrants and Settlement Warrants adjusted |  |  | 30,132,422 |  |  |  | 0.95 |  |  |  | – |
Exercised |  |  | (1,100,000 | ) |  |  | 0.95 |  |  |  | – |
Expired |  |  | – |  |  |  | – |  |  |  | – |
Outstanding, January 31, 2026 |  |  | 55,819,519 |  |  |  | 1.68 |  |  |  | 2.61 |
Exercisable, January 31, 2026 |  |  | 55,819,519 |  |  | $ | 1.68 |  |  |  | 2.61 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration